Incivek® Q2 2012 Sales Lighter Than Forecast; Full Year 2012 Trimmed

Vertex Pharmaceuticals just reported its Q2 2012 GAAP results — and the company’s shares are surging over 6 percent in NASDAQ after-hours trading — or $3 — to $53/share.

However, the Q2 split of US market sales is now more like 75 percent Incivek®, 25 percent Victrelis®. Presumably, as the colder weather months of 2012 arrive, the Incivek sales will accelerate, again.

See the Vertex SEC Form 8-K:

. . . .Full-Year Incivek Revenues: Vertex today revised guidance for full-year 2012 Incivek net revenues. The company expects full-year 2012 net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market. . . .

[Incivek sales were expected to range from $1.5 billion to $1.7 billion, as of February 2, 2012. . . .]

Still a very strong quarterly performance — by Vertex. Up 6% on the NASDAQ.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s